# US 2019/0194321 A1 · Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (trem-1)

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0194321 A1
- Document ID: US20190194321A1
- Status: Published application
- Kind: A1
- Application number: 16/209,627
- Filed: 2018-12-04
- Published: 2019-06-27
- Earliest claimed: 2012-02-15
- Assignees: Novo Nordisk A/S
- Applicants: Novo Nordisk A/S
- Inventors: Vibeke Westphal STENNICKE; Christine Brender READ; Susanne Nedergaard GRELL; Charlotte WIBERG; Rune SALBO; Anette HENRIKSEN; Soeren PADKJAER
- Web page: https://patentgrep.com/patent/US20190194321A1

## CPC

- C07K 16/2803: {against the immunoglobulin superfamily}
- A61K 2039/505: {comprising antibodies}
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/33: Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C07K 2317/34: Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C07K 2317/75: Agonist effect on antigen
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The invention relates to antibodies that are capable of specifically binding TREM-1 and preventing the activation of TREM-1, a protein expressed on monocytes, macrophages and neutrophils. Such antibodies find utility in the treatment of individuals with an inflammatory disease, such as rheumatoid arthritis and inflammatory bowel disease.

## Claims

### Claim at position 1

1-9. (canceled)

### Claim 10

An isolated antibody or fragment thereof, which competes with mAb 0170 for binding to a triggering receptor expressed on myeloid cells-1 (TREM-1) having an amino acid sequence set forth as SEQ ID NO: 1 (human TREM-1), SEQ ID NO: 12 or SEQ ID NO: 21 (cynomolgus monkey TREM-1),
wherein the antibody or fragment thereof comprises a heavy chain variable region that comprises CDR1, CDR2, and CDR3 domains; and a light chain variable region that comprises CDR1, CDR2, and CDR3 domains, and
wherein the heavy chain variable region CDR3 domain comprises amino acid residues 101 to 110 of SEQ ID NO: 4.

### Claim 11 (depends on 10)

The antibody or fragment thereof of claim 10, which specifically binds to D38 to F48 of SEQ ID NO: 1.

### Claim 12 (depends on 11)

The antibody or fragment thereof of claim 11, wherein the heavy chain variable region CDR2 domain comprises amino acid residues 50 to 68 of SEQ ID NO: 4 or amino acid residues 50 to 68 of SEQ ID NO: 4 with one, two, or three amino acid substitutions.

### Claim 13 (depends on 11)

The antibody or fragment thereof of claim 11, wherein the heavy chain variable region CDR1 domain comprises amino acid residues 31 to 35 of SEQ ID NO: 4 or amino acid residues 31 to 35 of SEQ ID NO: 4 with one amino acid substitution.

### Claim 14 (depends on 11)

The antibody or fragment thereof of claim 11, wherein the light chain variable region CDR3 domain comprises amino acid residues 93 to 101 of SEQ ID NO: 5 or amino acid residues 93 to 101 of SEQ ID NO: 5 with one or two amino acid substitutions.

### Claim 15 (depends on 11)

The antibody or fragment thereof of claim 11, wherein the light chain variable region CDR2 domain comprises amino acid residues 54 to 60 of SEQ ID NO: 5 or amino acid residues 54 to 60 of SEQ ID NO: 5 with one or two amino acid substitutions.

### Claim 16 (depends on 11)

The antibody or fragment thereof of claim 11, wherein the light chain variable region CDR1 domain comprises amino acid residues 24 to 38 of SEQ ID NO: 5 or amino acid residues 24 to 38 of SEQ ID NO: 5 with one, two, or three amino acid substitutions.

### Claim 17 (depends on 11)

The antibody or fragment thereof of claim 11, wherein the heavy chain variable region CDR1 domain comprises amino acid residues 31 to 35 of SEQ ID NO: 4 and wherein the heavy chain variable region CDR2 domain comprises amino acid residues 50 to 68 of SEQ ID NO: 4.

### Claim 18 (depends on 11)

The antibody or fragment thereof of claim 11, wherein the light chain variable region CDR3 domain comprises amino acid residues 93 to 101 of SEQ ID NO: 5 with one or two amino acid substitutions.

### Claim 19 (depends on 10)

The antibody or fragment thereof of claim 10, which binds human TREM-1 with a binding affinity (KD) that is or 1×10−9M or less, as determined using surface plasmon resonance.

### Claim 20 (depends on 10)

The antibody or fragment thereof of claim 10, which further comprises a heavy chain constant region which is of a human IgG1, IgG2, IgG3, or IgG4 isotype.

### Claim 21 (depends on 10)

The antibody or fragment thereof of claim 10, which further comprises a heavy chain constant region which is of a human IgG1 or IgG4 isotype.

### Claim 22 (depends on 10)

The antibody fragment of claim 10, which is a Fab, Fab′, F(ab)2, dAb, Fd, Fv, a single chain Fv fragment, or an isolated CDR.

### Claim 23 (depends on 10)

A pharmaceutical composition comprising the antibody or fragment thereof of claim 10 and a pharmaceutically acceptable carrier.

### Claim 24

A method of treating an autoimmune disease or chronic inflammation in a subject in need thereof comprising administering to the subject an antibody or fragment thereof which competes with mAb 0170 for binding to and blocking a triggering receptor expressed on myeloid cells-1 (TREM-1) having an amino acid sequence set forth as SEQ ID NO:1 (human TREM-1), SEQ ID NO:12 or SEQ ID NO:21 (cynomolgus monkey TREM-1).

### Claim 25 (depends on 24)

The method of claim 24, wherein the autoimmune disease is selected from the group consisting of rheumatoid arthritis, juvenile idiopathic arthritis, psoriasis, psoriatic arthritis, Crohn's disease, ulcerative colitis and systemic lupus erythematosus.

### Claim 26

An isolated nucleic acid encoding an antibody or fragment thereof which competes with mAb 0170 for binding to a triggering receptor expressed on myeloid cells-1 (TREM-1) having an amino acid sequence set forth as SEQ ID NO:1 (human TREM-1), SEQ ID NO:12 or SEQ ID NO:21 (cynomolgus monkey TREM-1).

### Claim 27 (depends on 26)

A vector comprising the nucleic acid of claim 26.

### Claim 28 (depends on 26)

A cell comprising the nucleic acid of claim 26.

### Claim 29 (depends on 28)

A method of making an antibody or fragment thereof which competes with mAb 0170 for binding to a triggering receptor expressed on myeloid cells-1 (TREM-1), comprising expressing the antibody in the cell of claim 28.
